| Tafenoquine in Patients With Mild to Moderate COVID-19 (NCT04533347) | 60 Degrees Pharmaceuticals LLC | 2021-02-19 |
| Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) (NCT04216589) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-02-19 |
| Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients (NCT04768179) | Makerere University | 2021-02-19 |
| PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (NCT04870333) | Cambridge University Hospitals NHS Foundation Trust | 2021-02-19 |
| Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation (NCT04711226) | Anelixis Therapeutics, LLC | 2021-02-19 |
| Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (NCT05476380) | Tianjin Medical University Cancer Institute and Hospital | 2021-02-19 |
| Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity (NCT04800159) | University of California, San Diego | 2021-02-19 |
| FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae (NCT04759001) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-02-18 |
| Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (NCT04676529) | Syntara | 2021-02-18 |
| Randomized Study of Obicetrapib as an Adjunct to Statin Therapy (NCT04753606) | NewAmsterdam Pharma | 2021-02-18 |
| Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder (NCT04410913) | Keith Heinzerling | 2021-02-18 |
| Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) (NCT04715932) | Montreal Heart Institute | 2021-02-18 |
| Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT04649073) | Otsuka Pharmaceutical Co., Ltd. | 2021-02-18 |
| Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 (NCT04779879) | Vir Biotechnology, Inc. | 2021-02-18 |
| Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study (NCT05022394) | M.D. Anderson Cancer Center | 2021-02-18 |
| Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens (NCT03978117) | Masonic Cancer Center, University of Minnesota | 2021-02-18 |
| Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma (NCT04758507) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-02-18 |
| Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy (NCT04745559) | H. Lee Moffitt Cancer Center and Research Institute | 2021-02-18 |
| Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL (NCT04685915) | Inhye Ahn | 2021-02-18 |
| Safety and Efficacy of Two Different Concentrations (0.5% and 1%) of Progesterone Topical Gel Compared to Placebo in Patients Diagnosed With Moderate to Severe Dry Eye Syndrome (NCT04645446) | SIFI SpA | 2021-02-18 |
| A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection (NCT04781647) | Assembly Biosciences | 2021-02-18 |
| Anti-PD1-antibody and Pulsed HHI for Advanced BCC (NCT04679480) | Reinhard Dummer | 2021-02-18 |
| Improving Therapeutic Learning for PTSD (NCT04558112) | University of Wisconsin, Madison | 2021-02-18 |
| Study of BBP-418 in Patients With LGMD2I (NCT04800874) | ML Bio Solutions, Inc. | 2021-02-18 |
| Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis (NCT04762953) | University of California, Irvine | 2021-02-18 |
| "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" (NCT05299580) | Fondazione Melanoma Onlus | 2021-02-18 |
| Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA) (NCT04699071) | National University Hospital, Singapore | 2021-02-18 |
| Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer (NCT04238988) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-02-18 |
| Letrozole in Patients With Hepatopulmonary Syndrome (NCT04577001) | Mayo Clinic | 2021-02-18 |
| Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia (NCT04629443) | Institut de Recherches Internationales Servier | 2021-02-17 |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (NCT04214249) | National Cancer Institute (NCI) | 2021-02-17 |
| Split-Dose R-CHOP for Older Adults With DLBCL (NCT03943901) | University of Wisconsin, Madison | 2021-02-17 |
| A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE (NCT04258683) | Canadian Myeloma Research Group | 2021-02-17 |
| Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies (NCT04504708) | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | 2021-02-17 |
| Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma. (NCT04775173) | West China Hospital | 2021-02-17 |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients (NCT04243122) | Ottawa Hospital Research Institute | 2021-02-17 |
| A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (NCT04623775) | Bristol-Myers Squibb | 2021-02-17 |
| Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (NCT04392037) | Amsterdam UMC, location VUmc | 2021-02-17 |
| AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer (NCT04630756) | AstraZeneca | 2021-02-17 |
| A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (NCT04767529) | Akero Therapeutics, Inc | 2021-02-16 |
| BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (NCT04284787) | National Cancer Institute (NCI) | 2021-02-16 |
| Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease (NCT04761848) | Sadat City University | 2021-02-16 |
| Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria (NCT04546633) | Novartis Pharmaceuticals | 2021-02-16 |
| The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis (NCT04767841) | Sadat City University | 2021-02-16 |
| Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease (NCT04723537) | RedHill Biopharma Limited | 2021-02-16 |
| Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder (NCT04753164) | Idorsia Pharmaceuticals Ltd. | 2021-02-16 |
| Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia (NCT04761861) | Sadat City University | 2021-02-16 |
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL (NCT04554459) | Institute of Hematology and Blood Transfusion, Czech Republic | 2021-02-16 |
| Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy (NCT05267392) | Instituto Portugues de Oncologia, Francisco Gentil, Porto | 2021-02-16 |
| Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia (NCT04342962) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2021-02-16 |
| To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older (NCT04754594) | BioNTech SE | 2021-02-16 |
| Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer (NCT04502407) | Cedars-Sinai Medical Center | 2021-02-16 |
| A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones (NCT04387617) | Mayo Clinic | 2021-02-15 |
| The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy (NCT04737967) | Mendel AI | 2021-02-15 |
| Antiviral Agents Against COVID-19 Infection (NCT04468087) | Hospital do Coracao | 2021-02-15 |
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 (NCT04360096) | APR Applied Pharma Research s.a. | 2021-02-15 |
| Dopaminergic Dysfunction in Late-Life Depression (NCT04469959) | Vanderbilt University Medical Center | 2021-02-15 |
| Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia (NCT04675151) | Ocuphire Pharma, Inc. | 2021-02-15 |
| Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19) (NCT04684550) | Hospital Universitario San Ignacio | 2021-02-15 |
| Effects of Ketones and Niacin in Heart Failure Patients (NCT04703361) | University of Aarhus | 2021-02-15 |
| Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease (NCT04552795) | The University of Texas Health Science Center at San Antonio | 2021-02-15 |
| SYN-004 Safety and Tolerability in Allo-HCT Subjects (NCT04692181) | Theriva Biologics, Inc. | 2021-02-15 |
| Totally Transdermal Sedation in the Weaning From Remifentanil Infusion (NCT04204967) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-02-15 |
| Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali (NCT04329104) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-02-15 |
| AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer (NCT04693234) | BeiGene | 2021-02-15 |
| Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders (NCT04761770) | Memorial Sloan Kettering Cancer Center | 2021-02-15 |
| Study to Assess the Effect of Meplazumab on COVID-19 (NCT04586153) | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | 2021-02-15 |
| Use of Autologous Plasma Rich in Platelets and Extracellular Vesicles in the Surgical Treatment of Chronic Middle Ear Infections (NCT04761562) | University Medical Centre Ljubljana | 2021-02-14 |
| Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation (NCT06865352) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2021-02-13 |
| Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer (NCT04641078) | University Hospital, Ghent | 2021-02-12 |
| A Study of Belcesiran in Patients With AATLD (NCT04764448) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2021-02-12 |
| A Study of TAK-019 in Healthy Japanese Adults (COVID-19) (NCT04712110) | Takeda | 2021-02-12 |
| Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer (NCT04762979) | Marina N Sharifi | 2021-02-12 |
| To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease (NCT04747977) | Ocular Therapeutix, Inc. | 2021-02-12 |
| Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose (NCT04278898) | Stanford University | 2021-02-12 |
| FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer (NCT04141995) | University of Nebraska | 2021-02-12 |
| Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) (NCT04345601) | Baylor College of Medicine | 2021-02-12 |
| Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. (NCT04648020) | Monopar Therapeutics | 2021-02-11 |
| Maternal Betaine Supplementation During Breastfeeding (NCT04633044) | Fundació Sant Joan de Déu | 2021-02-11 |
| Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration (NCT04584983) | The University of Texas Health Science Center, Houston | 2021-02-11 |
| Propranolol for Challenging Behaviors in Autism (NCT04047355) | Rutgers, The State University of New Jersey | 2021-02-11 |
| 5HTP Regulation Of Asthma In Children (NCT04160910) | Indiana University | 2021-02-11 |
| A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer (NCT04757363) | Memorial Sloan Kettering Cancer Center | 2021-02-11 |
| Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS (NCT04494789) | The George Institute | 2021-02-11 |
| Fibrosis and the Fontan (NCT04901975) | Children's Hospital of Philadelphia | 2021-02-11 |
| Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose (NCT04662866) | Oslo University Hospital | 2021-02-10 |
| Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y) (NCT04748471) | Assistance Publique - Hôpitaux de Paris | 2021-02-10 |
| Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19 (NCT04954040) | Maimónides Biomedical Research Institute of Córdoba | 2021-02-10 |
| A Proof-of-principle Clinical Study Investigating the Efficacy of an Experimental Dentifrice Containing Sodium Bicarbonate and Sodium Hyaluronate on Gingivitis (NCT04737538) | GlaxoSmithKline | 2021-02-10 |
| Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer (NCT04721132) | M.D. Anderson Cancer Center | 2021-02-10 |
| Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 (NCT04824391) | Health Institutes of Turkey | 2021-02-10 |
| Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma (NCT04804696) | Peking University | 2021-02-10 |
| TXA127 for the Treatment of Severe COVID-19 (NCT04401423) | Columbia University | 2021-02-10 |
| Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy (NCT04149821) | Weill Medical College of Cornell University | 2021-02-10 |
| Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras (NCT04771013) | Universidad Católica de Honduras | 2021-02-10 |
| Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis (NCT04517851) | M.D. Anderson Cancer Center | 2021-02-10 |
| OCS-05 in Patients With Optic Neuritis (NCT04762017) | Oculis | 2021-02-10 |
| Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma (NCT04632433) | Fondazione Melanoma Onlus | 2021-02-10 |
| DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) (NCT04567420) | Criterium, Inc. | 2021-02-09 |
| A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN) (NCT04702997) | Biogen | 2021-02-09 |